Phase 2 clinical data of DARA’s leading drug candidate KRN5500 will be presented at 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain which will be held on 11/19-11/21(Thursday-Saturday), If positive data is released, DARA will break the ceiling without doubt.
Besides KRN5500 for Chronic neuropathic pain, DARA also has a therapy portfolio for type 2 diabetes which includes DB959, DB160 &DB900, and DB200 for psoriasis.
DARA has only 15M market cap, but KRN5500 alone is worth more than the entire market value.
It is obvious that the current stock price .46 is way under value.
There is a recent recommendation for DARA, check it out!
http://finance.yahoo.com/news/SmallCap-DARA-Bio-Worth-a-zacks-628902537.html?x=0&.v=1
| Zacks Top Ten Stocks for 2011 are now available! This 10-stock portfolio is a well-balanced mix of aggressive and conservative, large and small cap, growth and value. Buy them. Hold them. Watch your gains add up |
| With Zacks Method for Trading you'll transform yourself into a Master Stock Trader, one simple step at a time. Get step-by-step instructions and learn how to use the 28% per year Zacks Rank system to find market-beating stocks on your own, fully exploiting the system that beat the market 18 of the last 20 years. Find out how >> |
| Stock screening and chart patterns expert, Kevin Matras, combs through the best Zacks stock-picking strategies averaging +60% yearly gains to find stocks with charts showing they are ready to skyrocket. Chart Patterns Trader >> |
|
Ride Momentum Stocks to Quick Gains! The market is finally breaking out, creating the perfectd wave for investing in momentum stocks. Zacks is the king of fundamental analysis, but this service also uses technical indicators for the best possible timing. Click here to learn more >>. |

Read AndrewGreenBull's blog in RSS
November 17, 2009
Share This